ISPAD Clinical Practice Consensus Guidelines 2024: Glycemic Targets
The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and updates recommendations on the glycemic targets for children and adolescents living with diabetes. A new target for hemoglobin A1c (HbA1c) of ≤6.5% (48 mmol/mol) is recommended for those who have access to advanced diabetes technologies like continuous glucose monitoring and automated insulin delivery. This target should be encouraged for all children and adolescents living with diabetes when safely achievable. In other settings, the HbA1c target is ≤7.0% (53 mmol/mol). The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and updates recommendations on the glycemic targets for children and adolescents living with diabetes. A new target for hemoglobin A1c (HbA1c) of ≤6.5% (48 mmol/mol) is recommended for those who have access to advanced diabetes technologies like continuous glucose monitoring and automated insulin delivery. This target should be encouraged for all children and adolescents living with diabetes when safely achievable. In other settings, the HbA1c target is ≤7.0% (53 mmol/mol).
Authors
- Klemen Dovč (ORCID: https://orcid.org/0000-0001-9201-2145)
- Carmel E. Smart (ORCID: https://orcid.org/0000-0003-3104-8800)
- Yeray Nóvoa Medina (ORCID: https://orcid.org/0000-0002-9564-0654)
- Martin de Bock (ORCID: https://orcid.org/0000-0003-0454-6679)
- Linda Anne DiMeglio (ORCID: https://orcid.org/0000-0002-8033-6078)
- Farid H. Mahmud (ORCID: https://orcid.org/0000-0002-3557-3584)
- Leena Priyambada (ORCID: https://orcid.org/0000-0003-2146-1108)
- Maria Loredana Marcovecchio (ORCID: https://orcid.org/0000-0002-4415-316X)
- Juliana Chizo Agwu (ORCID: https://orcid.org/0000-0002-8593-187X)
- David M. Maahs (ORCID: https://orcid.org/0000-0002-4602-7909)
- Matt Deabreu
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- University of Toronto (CA)
- University of Cambridge (GB)
- Hospital for Sick Children (CA)
- Ljubljana University Medical Centre (SI)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Riley Hospital for Children (US)
- Diabetes Canada (CA)
- John Hunter Children's Hospital (AU)
- SickKids Foundation (CA)
- Wye Valley NHS Trust (GB)
- Rainbow Children's Hospital (IN)
- Indiana University – Purdue University Indianapolis (US)
- University of Newcastle Australia (AU)
- University of Otago (NZ)
- Stanford University (US)
Publication Details
- Journal
- Hormone Research in Paediatrics
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1159/000543266
- Citations
- 22
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.87
Funders
- Sanofi
- Dexcom
- Abbott Diabetes Care